Phase 2 N=74 Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
Acute Myeloblastic Leukemia
Primary: Cumulative Incidence of Non Relapse Mortality (NRM) — 21 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=722 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Subjects in Complete Remission at Month 12 of Maintenance Phase — 47.8; 26.0 percentage of subjects — p=<0.001
Phase 3 N=326 A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Acute Myelogenous Leukemia
Primary: Overall Survival - Overall and by Calculated Strata (CSR 7-April-11) — 6.6; 6.4; 5.1; 5.5 months — p=0.9951
Phase 2 N=80 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants
Phase 2 N=47 Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Phase 2 N=115 S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Phase 2 N=40 Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
CD20 Positive · Hematopoietic and Lymphoid Cell Neoplasm · Lymphocytic Neoplasm
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=41 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
B-Cell Non-Hodgkin Lymphoma · Hematopoietic and Lymphoid Cell Neoplasm · Leukemia
Primary: Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant — 10; 2 Participants
Phase 2 N=25 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Phase 2 N=87 Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Hodgkin's Disease · Lymphoma, Non-Hodgkin
Primary: Maximum Tolerated Dose (MTD) of 90Y-HAT — 15 mci
Phase 4 N=181 Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
Depression
Primary: Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS) — 44; 29 percentage of participants
Phase 3 N=146 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
B-cell Childhood Acute Lymphoblastic Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission · Graft Versus Host Disease
Primary: Estimated Percentage of Participants With Event Free Survival — 45; 54 percentage of participants
Phase 3 N=472 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
Leukemia, Myeloid, Acute
Primary: Kaplan-Meier (K-M) Estimate for Overall Survival (OS) — 24.7; 14.8 Months — p=0.0009
Phase 2 N=60 CFAR Study in Patients With Chronic Lymphocytic Leukemia
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Phase 2 N=77 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants